Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.

Komiya T, Memmott RM, Blumenthal GM, Bernstein W, Ballas MS, De Chowdhury R, Chun G, Peer CJ, Figg WD, Liewehr DJ, Steinberg SM, Giaccone G, Szabo E, Kawabata S, Tsurutani J, Rajan A, Dennis PA.

Transl Lung Cancer Res. 2019 Jun;8(3):247-257. doi: 10.21037/tlcr.2019.04.19.


A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.

Komiya T, Blumenthal GM, DeChowdhury R, Fioravanti S, Ballas MS, Morris J, Hornyak TJ, Wank S, Hewitt SM, Morrow B, Memmott RM, Rajan A, Dennis PA.

Oncologist. 2019 Jul 26. pii: theoncologist.2019-0514. doi: 10.1634/theoncologist.2019-0514. [Epub ahead of print]


Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.

Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA.

Oncotarget. 2014 Feb 28;5(4):1062-70.


Repositioning metformin for cancer prevention and treatment.

Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA.

Trends Endocrinol Metab. 2013 Sep;24(9):469-80. doi: 10.1016/j.tem.2013.05.004. Epub 2013 Jun 15. Review.


Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.

Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA.

Cancer Prev Res (Phila). 2013 Aug;6(8):801-10. doi: 10.1158/1940-6207.CAPR-13-0058-T. Epub 2013 Jun 14.


Metformin prevents tobacco carcinogen--induced lung tumorigenesis.

Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA.

Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76. doi: 10.1158/1940-6207.CAPR-10-0055. Epub 2010 Sep 1.


The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis.

Memmott RM, Dennis PA.

Clin Cancer Res. 2010 Jan 1;16(1):4-10. doi: 10.1158/1078-0432.CCR-09-0234. Epub 2009 Dec 22.


LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.

Memmott RM, Dennis PA.

J Clin Oncol. 2009 Dec 1;27(34):e226; author reply e227. doi: 10.1200/JCO.2009.25.3963. Epub 2009 Oct 26. No abstract available.


The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.

Han W, Gills JJ, Memmott RM, Lam S, Dennis PA.

Cancer Prev Res (Phila). 2009 Apr;2(4):370-6. doi: 10.1158/1940-6207.CAPR-08-0209. Epub 2009 Mar 31.


A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis.

Granville CA, Memmott RM, Balogh A, Mariotti J, Kawabata S, Han W, Lopiccolo J, Foley J, Liewehr DJ, Steinberg SM, Fowler DH, Hollander MC, Dennis PA.

PLoS One. 2009;4(3):e5061. doi: 10.1371/journal.pone.0005061. Epub 2009 Mar 30.


Akt-dependent and -independent mechanisms of mTOR regulation in cancer.

Memmott RM, Dennis PA.

Cell Signal. 2009 May;21(5):656-64. doi: 10.1016/j.cellsig.2009.01.004. Epub 2009 Jan 7. Review.


A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity.

Palumbo SL, Memmott RM, Uribe DJ, Krotova-Khan Y, Hurley LH, Ebbinghaus SW.

Nucleic Acids Res. 2008 Apr;36(6):1755-69. doi: 10.1093/nar/gkm1069. Epub 2008 Feb 5.


Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.

Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A, Dennis PA.

Cancer Res. 2008 Jan 15;68(2):580-8. doi: 10.1158/0008-5472.CAN-07-3091.


Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms.

Gills JJ, Castillo SS, Zhang C, Petukhov PA, Memmott RM, Hollingshead M, Warfel N, Han J, Kozikowski AP, Dennis PA.

J Biol Chem. 2007 Sep 14;282(37):27020-9. Epub 2007 Jul 13.


Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

Granville CA, Memmott RM, Gills JJ, Dennis PA.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89. Review.

Supplemental Content

Loading ...
Support Center